TD Asset Management
TARA icon

TD Asset Management’s Protara Therapeutics TARA Stock Holding History

TD Asset Management’s Portfolio TARA Stock Details TARA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-25,185
Closed -$396K – 1568
2021
Q1 		$396K Hold
25,185
– – ﹤0.01% 1429
2020
Q4 		$610K Hold
25,185
– – ﹤0.01% 1293
2020
Q3 		$424K Buy
+25,185
New +$584K ﹤0.01% 1277

Other funds holding TARA

OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

TD Asset Management's TARA Position: Q2 2021 in Review

TD Asset Management sold out of Protara Therapeutics (TARA) in Q2 2021, closing a stake of 25,185 shares — an estimated $396K sold.

TD Asset Management first reported a position in TARA in Q3 2020 and held it in 3 quarters. The position peaked at $610K in Q4 2020. 41 funds tracked by Wall St. Rank hold TARA as of Q2 2021.

  • TD Asset Management reported no remaining Protara Therapeutics position as of Q2 2021 after selling out during the quarter.
  • TD Asset Management sold 25,185 Protara Therapeutics shares in Q2 2021, an estimated $396K.
  • TD Asset Management first reported a position in Protara Therapeutics in Q3 2020 and held it in 3 quarters.
  • TD Asset Management's Protara Therapeutics position peaked at $610K in Q4 2020.
  • 41 funds tracked by Wall St. Rank held Protara Therapeutics as of Q2 2021.

Based on TD Asset Management's 13F filing for Q2 2021, filed 11 Aug 2021.